A Double-blind (Sponsor Unblinded) Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Repeat Dosing of GSK2646264 in Cutaneous Lupus Erythematosus Patients
Latest Information Update: 05 Sep 2023
At a glance
- Drugs GSK 2646264 (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 10 Aug 2018 Status changed from active, no longer recruiting to completed.
- 06 Aug 2018 Planned End Date changed from 31 Jul 2018 to 8 Aug 2018.
- 02 Aug 2018 Planned End Date changed from 12 Jun 2018 to 31 Jul 2018.